Skip to content
10-Q

Quarterly Report

CytomX Therapeutics, Inc. CTMX

0001193125-26-211868

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 217.7M sh
Shares Diluted Q1 2026 · Mar 31, 2026 177.27M sh
Shares Diluted Q1 2026 · Mar 31, 2025 87.15M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $119K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$25.55M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$21.04M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $28.83M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $12.67M
Stockholders Equity Q1 2026 · Mar 31, 2026 $319.94M
Stockholders Equity Q1 2026 · Dec 31, 2025 $99.01M
Stockholders Equity Q1 2026 · Mar 31, 2025 $25.05M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$456K
Current Liabilities Q1 2026 · Mar 31, 2026 $34.02M
Current Liabilities Q1 2026 · Dec 31, 2025 $46.62M
Total Liabilities Q1 2026 · Mar 31, 2026 $39.41M
Total Liabilities Q1 2026 · Dec 31, 2025 $52.56M
Current Assets Q1 2026 · Mar 31, 2026 $353.1M
Current Assets Q1 2026 · Dec 31, 2025 $143.92M
Total Assets Q1 2026 · Mar 31, 2026 $359.36M
Total Assets Q1 2026 · Dec 31, 2025 $151.57M
Sga Expense Q1 2026 · Mar 31, 2026 $10.69M
Sga Expense Q1 2026 · Mar 31, 2025 $9.43M
Rd Expense Q1 2026 · Mar 31, 2026 $19.24M
Rd Expense Q1 2026 · Mar 31, 2025 $18.87M
Net Income Q1 2026 · Mar 31, 2026 −$18.25M
Net Income Q1 2026 · Mar 31, 2025 $23.53M
Operating Income Q1 2026 · Mar 31, 2026 −$19.67M
Operating Income Q1 2026 · Mar 31, 2025 $22.62M
Revenue Q1 2026 · Mar 31, 2026 $10.26M
Revenue Q1 2026 · Mar 31, 2025 $50.92M